B72 Stock Chart & Stats
€3.64
-€0.07(-3.75%)
At close: 4:00 PM EST
€3.64
-€0.07(-3.75%)
Day’s Range― - ―
52-Week Range€2.13 - €6.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.50K
Market Cap
€1.67B
Enterprise Value€1.46B
Total Cash (Recent Filing)€230.77M
Total Debt (Recent Filing)€2.00M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 12, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.00
Shares Outstanding368,166,700
10 Day Avg. Volume3,534
30 Day Avg. Volume1,499
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.10Price Target Upside287.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.38
Revenue Forecast (FY)€1.28M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseVery low leverage and a meaningful equity cushion provide durable financial flexibility to support multi-year clinical programs. This reduces near-term solvency risk, enables strategic R&D funding or partnerships without immediate distress, and lengthens runway versus peers reliant on debt.
Exceptionally High Reported Gross MarginsA very high gross margin implies the company's science/IP and potential therapies can scale revenue with limited COGS, making future commercialization or licensing highly accretive to margins. If clinical success occurs, revenue conversion to operating profit could be favorable.
Index Inclusion Expands Investor BaseBeing added to major Russell indexes is a structural change that typically increases passive fund ownership and liquidity. This broadens the investor base, eases future capital raises, and stabilizes secondary market access, supporting long-term financing and M&A optionality.
Bears Say
Large And Persistent Cash BurnSustained negative operating and free cash flow indicates the business requires external financing to sustain R&D and operations. Persistent burn raises dilution risk, limits strategic optionality, and places pressure on management to secure partnerships or equity raises within the next 2-6 months.
Minimal And Declining Revenue ScaleTiny and falling revenues reflect lack of commercialized products and limited near-term cash generation. This weak revenue base means operating expenditures are not supported by sales, increasing reliance on external funding and making operating leverage and break-even distant.
Deep Negative Margins And Widening LossesExtremely negative margins and expanding losses erode equity value and signal that current operations destroy cash long-term. Unless clinical or licensing milestones materialize, ongoing deficits increase capital needs and amplify shareholder dilution and business-model risk.
Atai Beckley N.V. News
B72 FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was €2.13 and its highest was €6.00 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is €1.67B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were Atai Beckley N.V.’s earnings last quarter?
Atai Beckley N.V. released its earnings results on May 12, 2026. The company reported -€0.07 earnings per share for the quarter, beating the consensus estimate of -€0.094 by €0.024.
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. does not currently pay dividends.
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate is -0.1.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 368,166,700 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Atai Beckley N.V. reported an EPS of -€0.07 in its last earnings report, beating expectations of -€0.094. Following the earnings report the stock price went down -2.247%.
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in DE:B72
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Company Description
Atai Beckley N.V.
Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.
B72 Stock 12 Month Forecast
Average Price Target
€14.10
▲(287.46% Upside)
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Options Prices
Currently, No data available
---